Spago Nanomedical
LUND, SWEDEN / ACCESSWIRE / December 6, 2021 / Spago Nanomedical (STO:SPAGO.ST) (FRA:7UX.F)
Spago Nanomedical AB (publ) today announced it has completed the studies in the regulatory preclinical program with its leading candidate drug Tumorad (SN201). It displays a good safety margin to clinically relevant doses.
"The completion of the regulatory preclinical studies is an important step towards the clinical development phase. The preparations for the first study with SN201 in humans are proceeding according to plan and we expect to be ready to start phase I/II in next year ", said CEO Mats Hansen.
The preclinical package included toxicology- and dosimetry-studies in rat. The results showed that the nanomaterial is safe to give in doses that widely exceed planned clinical doses, and that radiation is distributed in the body in a manner that allow dosing according to plan.
"The results confirm the data we previously have seen in pilot studies and mean that we with confidence can proceed with SN201 to the clinic. This is a major risk reduction in the project ", said Oskar Axelsson, CSO at Spago Nanomedical.
Data from the preclinical studies, together with other documentation, will form the basis for the first clinical trial application with Tumorad. The plan is to submit the application and start the studies in humans in 2022. The aim for the clinical study is to document safety at different doses of Tumorad in cancer patients as well as to evaluate signs of early proof-of-concept.
The preclinical regulatory program, conducted in collaboration with Charles River Laboratories and Minerva Imaging, included both toxicity and dosimetry studies.
For further information, please contact Mats Hansen, CEO Spago Nanomedical AB, +46 46 811 88, mats.hansen@spagonanomedical.se
Spago Nanomedical AB is a Swedish nanomedicines company in clinical development phase. The company´s development projects are based on a platform of polymeric materials with unique properties for more precise diagnosis and treatment of solid tumors. Spago Nanomedical´s share is listed on Nasdaq First North Growth Market (ticker: SPAGO). For further information, see www.spagonanomedical.se.
FNCA Sweden AB is the Certified Adviser of the company, +46 8 528 00 399, info@fnca.se .
This information is information that Spago Nanomedical is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-12-06 08:00 CET.
Attachments
Tumorad® shows good safety in preclinical studies
SOURCE: Spago Nanomedical
View source version on accesswire.com:
https://www.accesswire.com/676127/TumoradR-Shows-Good-Safety-in-Preclinical-Studies
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Richter Extends Its Support to Africa - The First Year of the House of Hope in Bamako in Numbers26.1.2026 14:00:00 CET | Press release
The First Year of the House of Hope in Bamako in Numbers BUDAPEST, HU / ACCESS Newswire / January 26, 2026 / Nearly one year has passed since the House of Hope centre, established by Richter Gedeon Plc., began providing shelter and comprehensive support to women in Bamako. During this period, almost 120 women and girls have benefited from healthcare, legal aid and education. Interest in the centre remains strong, with new women continuously joining the programme. In the coming years, the initiative aims to reach several hundred vulnerable women across different regions of Mali. Why Was the House of Hope Established? The centre was created through the collaboration of Richter Gedeon Plc. (Richter), the Hungary-based Close to Africa Foundation, and the local Sini Sanuman Foundation. Its mission is to provide safety and professional support to women fleeing violence and abuse through gynaecological care, psychological and legal counselling, and educational programmes. The building was des
Datavault AI to Support Establishment of International Research Center Focused on Real-World Asset Digitization in Taiwan26.1.2026 12:00:00 CET | Press release
PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 26, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI" or the "Company"), a leader in data monetization, credentialing, digital engagement and real‑world asset ("RWA") tokenization technologies, today announced the execution of a memorandum of understanding with St. John's University in Taipei to support the establishment of the RWA International Research Center (the "Center"). The Center will serve as a core platform for promoting inter-university alliances and international industry-academia collaboration, as well as for advancing the study of real-world asset tokenization frameworks, regulatory technology, and applied financial innovation. The Center is scheduled to be inaugurated on St. John's University's campus on January 26, 2026. The collaboration is expected to be structured as an academic and applied research initiative focused on advancing standards, education, and cross-disciplinary collaboration to support the resp
Masar Destination Achieves LEED for Communities Gold Certification23.1.2026 21:35:00 CET | Press release
Affirming its Commitment to Sustainability MAKKAH, SAUDI ARABIA / ACCESS Newswire / January 23, 2026 / Masar: a landmark urban development in the heart of Makkah, owned, developed, and operated by Umm Al Qura for Development & Construction Company, has been awarded LEED Gold certification under the LEED for Communities rating system, one of the highest international certifications in sustainability and the built environment. This achievement recognizes Masar's adoption of an integrated approach that places people and the environment at the heart of its design and planning processes. This accomplishment reflects the company's commitment to developing sustainable urban communities in line with global best practices. By balancing quality of life, resource efficiency, and environmental protection, it paves the way for long-term positive impact and a more sustainable future. Commenting on the achievement, Mr. Yasser Abuateek, Chief Executive Officer of Umm Al Qura for Development & Construc
Sir Ivan Releases "Love Is The Piece"23.1.2026 20:45:00 CET | Press release
The Peace Anthem of the 21st Century MIAMI, FLORIDA / ACCESS Newswire / January 23, 2026 / Electronic Dance Music (EDM) recording artist, Sir Ivan, has co-written and recorded a peace song that will stand the test of time. Inspired by 20th-century anti-war rock legends such as John Lennon and Bob Dylan, Sir Ivan's new single, "Love Is The Piece," is a bold reminder to all generations that love remains the only path to peace and is found only in our hearts. Stream/Download On All Platforms "As the son of an Auschwitz survivor (see UnstoppableSiggi.com), my life has been deeply affected by the tragedy of having over 50 family members murdered during the Holocaust, simply because they were Jewish. My father's miraculous survival and my subsequent birth had a purpose. And that purpose was for me to one day write and sing a peace song that would help stop violence, bloodshed, and war between people. That song is ‘Love Is The Piece,'" declared Sir Ivan. While global conflicts and civil unres
From NASA to Your Boardroom: Freelancer Opens 85-Million-Mind Innovation Engine to All Enterprises23.1.2026 14:00:00 CET | Press release
The platform that slashed NASA's R&D costs and compressed three-day computations into one hour is now available to any organisation Previous challenge winner's spacecraft solution is bound for space What do you do when your toughest technical problem stumps every expert in your building? If you're NASA, you throw it open to 85 million minds across 140 countries. Starting today, any company can do the same. SAN FRANCISCO, CA / ACCESS Newswire / January 23, 2026 / Freelancer (ASX:FLN) announced the global launch of its Moonshot Innovation Program, opening the breakthrough platform that has delivered over 20,000 solutions to NASA, NIH, and the CDC to enterprises worldwide. The same system that helped NASA save 80-99% on R&D costs, compressed Bureau of Reclamation river modelling from 72 hours to 60 minutes, and generated 54 genome therapy breakthroughs for NIH is now available to any organization with a problem that traditional consulting can't crack. The results speak louder than any pit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom